

Neurolysin degrades neurotensin

Jupe, S., Karamyan, VT.

European Bioinformatics Institute, New York University Langone Medical Center, Ontario Institute for Cancer Research, Oregon Health and Science University.

The contents of this document may be freely copied and distributed in any media, provided the authors, plus the institutions, are credited, as stated under the terms of [Creative Commons Attribution 4.0 International \(CC BY 4.0\) License](#). For more information see our [license](#).

08/09/2021

Introduction

Reactome is open-source, open access, manually curated and peer-reviewed pathway database. Pathway annotations are authored by expert biologists, in collaboration with Reactome editorial staff and cross-referenced to many bioinformatics databases. A system of evidence tracking ensures that all assertions are backed up by the primary literature. Reactome is used by clinicians, geneticists, genomics researchers, and molecular biologists to interpret the results of high-throughput experimental studies, by bioinformaticians seeking to develop novel algorithms for mining knowledge from genomic studies, and by systems biologists building predictive models of normal and disease variant pathways.

The development of Reactome is supported by grants from the US National Institutes of Health (P41 HG003751), University of Toronto (CFREF Medicine by Design), European Union (EU STRP, EMI-CD), and the European Molecular Biology Laboratory (EBI Industry program).

Literature references

- Fabregat, A., Sidiropoulos, K., Viteri, G., Forner, O., Marin-Garcia, P., Arnau, V. et al. (2017). Reactome pathway analysis: a high-performance in-memory approach. *BMC bioinformatics*, 18, 142. [↗](#)
- Sidiropoulos, K., Viteri, G., Sevilla, C., Jupe, S., Webber, M., Orlic-Milacic, M. et al. (2017). Reactome enhanced pathway visualization. *Bioinformatics*, 33, 3461-3467. [↗](#)
- Fabregat, A., Jupe, S., Matthews, L., Sidiropoulos, K., Gillespie, M., Garapati, P. et al. (2018). The Reactome Pathway Knowledgebase. *Nucleic Acids Res*, 46, D649-D655. [↗](#)
- Fabregat, A., Korninger, F., Viteri, G., Sidiropoulos, K., Marin-Garcia, P., Ping, P. et al. (2018). Reactome graph database: Efficient access to complex pathway data. *PLoS computational biology*, 14, e1005968. [↗](#)

Reactome database release: 77


This document contains 1 reaction ([see Table of Contents](#))

Neurolysin degrades neurotensin [↗](#)

Stable identifier: R-HSA-8940959

Type: transition

Compartments: extracellular region



Neurolysin (NLN, EC 3.4.24.16) is a member of the thermolysin-like mammalian zinc endopeptidase family (Dauch et al. 1995). It is maximally active at neutral pH and responsible for hydrolytic processing of bioactive peptides in the extracellular environment (Shrimpton et al. 2002). It cleaves 3 residues from the C-terminal end of Neurotensin (Dauch et al. 1995).

Other endogenous substrates of NLN include bradykinin, angiotensins I and II, substance P, hemo-pressin, dynorphin A(1–8), metorphamide, and somatostatin (Wangler et al. 2016). The functional significance of NLN is poorly understood (Checler 2014). In vivo studies have linked it to neurotensin-dependent nociception (Vincent et al. 1997), bradykinin-mediated hypotension, microvascular permeability and hyperalgesia (Gomez et al. 2011), and pathogenesis of stroke (Rashid et al. 2014).

Literature references

Wangler, NJ., Jayaraman, S., Zhu, R., Mechref, Y., Abbruscato, TJ., Bickel, U. et al. (2016). Preparation and preliminary characterization of recombinant neurolysin for in vivo studies. *J. Biotechnol.*, 234, 105-15. [↗](#)

Checler, F., Vincent, JP., Kitabgi, P. (1986). Purification and characterization of a novel neurotensin-degrading peptidase from rat brain synaptic membranes. *J. Biol. Chem.*, 261, 11274-81. [↗](#)

Editions

2016-09-27	Authored	Jupe, S.
2016-10-19	Edited	Jupe, S.
2016-10-19	Reviewed	Karamyan, VT.